Form SCHEDULE 13D - General Statement of Acquisition of Beneficial Ownership:
SEC Accession No. 0001104659-25-045628
Filing Date
2025-05-07
Accepted
2025-05-07 17:11:07
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D  
1 primary_doc.xml SCHEDULE 13D 16874
2 EXHIBIT 4 tm2514381d1_ex-4.htm EX-99.4 4531
  Complete submission text file 0001104659-25-045628.txt   23189
Mailing Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623
Business Address 6 CENTERPOINTE DR. #625 LA PALMA CA 90623 213-273-5453
Liminatus Pharma, Inc. (Subject) CIK: 0001971387 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D | Act: 34 | File No.: 005-95001 | Film No.: 25922688
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address C/O LIMINATUS PHARMA, INC. LA PALMA CA 90623
Business Address C/O LIMINATUS PHARMA, INC. LA PALMA CA 90623 213-273-5453
Valetudo Therapeutics LLC (Filed by) CIK: 0002067359 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D